Celldex Therapeutics, Inc. (NASDAQ:CLDX) Files An 8-K Other Events
Item 8.01. Other Events.

On April 16, 2018, Celldex Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company’s Phase 2b METRIC Study of glembatumumab vedotin in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint. Based on these results, the Company has made the decision to discontinue the glembatumumab vedotin program across all indications. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

See Exhibit Index attached hereto.

(d) Exhibits

99.1Press Release of Celldex Therapeutics, Inc., dated April 16, 2018.

Celldex Therapeutics, Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Celldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary EndpointConference Call Scheduled for 8:00 a.m. ET Today HAMPTON,…
To view the full exhibit click here

About Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.